Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Tongji Hospital
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07417501CT.gov Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification | — | Not Yet Recruiting | — | — | — |
NCT06161558CT.gov Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors | — | Withdrawn | — | — | — |
NCT06739395CT.gov Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion | — | Recruiting | — | — | — |
NCT06036836CT.gov Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | — | Completed | — | — | — |
NCT05767684CT.gov Neoantigen Derived DCs as Cancer Treatment | — | Unknown | — | — | — |
NCT05620134CT.gov Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | — | Active Not Recruiting | — | — | — |
NCT05273554CT.gov A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma | — | Active Not Recruiting | — | — | — |
NCT05740215CT.gov Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors | — | Unknown | — | — | — |
NCT04955743CT.gov Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma | — | Terminated | — | — | — |
NCT05064280CT.gov Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases | — | Recruiting | — | — | — |
Show 11 more trialsShow fewer
NCT05024214CT.gov Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors | — | Recruiting | — | — | — |
NCT04729348CT.gov Pembrolizumab And Lenvatinib In Leptomeningeal Metastases | — | Terminated | — | — | — |
NCT04300556CT.gov A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | — | Recruiting | — | — | — |
NCT04008797CT.gov A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | — | Active Not Recruiting | — | — | — |
NCT03486873CT.gov Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | — | Recruiting | — | — | — |
NCT03477175CT.gov Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials | — | Completed | — | — | — |
NCT03564691CT.gov Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001) | — | Completed | — | — | — |
NCT03006887CT.gov Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors | — | Completed | — | — | — |
NCT02720068CT.gov Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) | — | Completed | — | — | — |
NCT02640508CT.gov Eribulin and Lenvatinib in Advanced Solid Tumors | — | Completed | — | — | — |
NCT02501096CT.gov A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lenvatinib (this asset) | Tongji Hospital | P3 | B · 60 |
| Panitumumab | Astellas Pharma Inc | P2 | BBB |
| Granulocyte Colony-Stimulating Factor Lenograstim | Sanofi | P4 | BB |
| Dexmedetomidine | Medical College of Wisconsin | P4 | BB |
| Lidocaine | Medical College of Wisconsin | P4 | BB |
| Relatlimab | Bristol-Myers Squibb | P2 | BB |
| Vitamin D | Tanta University | P4 | BB |
| Glycopyrrolate | Medical College of Wisconsin | P4 | BB |
| Dinitrogen Monoxide | Medical College of Wisconsin | P4 | BB |
+42 more in the Neoplasm cohort
Other indications for Lenvatinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Portal Vein Thrombosis | — | P4 | BBB · 73 |
| Ovarian Carcinoma | — | P4 | BB · 70 |
| Hepatocellular Carcinoma | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lenvatinib in Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lenvatinib-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →